-+ 0.00%
-+ 0.00%
-+ 0.00%
Hengrui Pharmaceutical announced that Beijing Shengdi Pharmaceutical, a subsidiary of the company, received a notice from the State Drug Administration to approve the marketing of the new class 1 drug refusibizumab injection independently developed by the company. This drug is used to treat homozygous familial hypercholesterolemia in adults and adolescents aged 12 and above to reduce LDL cholesterol levels. Up to now, this drug-related project has invested about 303 million yuan in R&D.
Share
Listen to the news
Hengrui Pharmaceutical announced that Beijing Shengdi Pharmaceutical, a subsidiary of the company, received a notice from the State Drug Administration to approve the marketing of the new class 1 drug refusibizumab injection independently developed by the company. This drug is used to treat homozygous familial hypercholesterolemia in adults and adolescents aged 12 and above to reduce LDL cholesterol levels. Up to now, this drug-related project has invested about 303 million yuan in R&D.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending